Immunotherapy for neurological diseases

Clinical Immunology

Volumn 128, Issue 3, 2008, Pages 294-305

  Villoslada, Pablo ^a   Moreno, Beatriz ^a   Melero, Ignacio ^a   Pablos, Jose L ^b   Martino, Gianvito ^c   Uccelli, Antonio ^d   Montalban, Xavier ^e   Avila, Jesus ^f   Rivest, Serge ^g   Acarin, Laia ^h   Appel, Stanley ⁱ   Khoury, Samia J ^j   McGeer, Patrick ^k   Ferrer, Isidro ^l   Delgado, Mario ^m   Obeso, Jose ^a   Schwartz, Michal ⁿ  

^a UNIVERSITY OF NAVARRA   (Spain)

^b HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^c SAN RAFFAELE HOSPITAL   (Italy)

^d UNIVERSITY OF GENOA   (Italy)

^e HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^f UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

^g LAVAL UNIVERSITY   (Canada)

^h UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

ⁱ HOUSTON METHODIST RESEARCH INSTITUTE   (United States)

^j MASSACHUSETTS GENERAL HOSPITAL   (United States)

^k UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^l HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^m INSTITUTO DE PARASITOLOGÍA Y BIOMEDICINA LÓPEZ NEYRA   (Spain)

ⁿ WEIZMANN INSTITUTE OF SCIENCE   (Israel)

more..

Author keywords

Alzheimer disease; Amyotrophic lateral sclerosis; Cell therapy; Immunotherapy; Multiple sclerosis; Neurological diseases; Neuroprotection; Parkinson disease; Stem cells; Vaccination

Indexed keywords

ABATACEPT; ACETYLSALICYLIC ACID; ADALIMUMAB; ATLIZUMAB; BETA INTERFERON; ETANERCEPT; FINGOLIMOD; GLATIRAMER; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INFLIXIMAB; MELOXICAM; MINOCYCLINE; NATALIZUMAB; NONSTEROID ANTIINFLAMMATORY AGENT; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RILUZOLE; RITUXIMAB; ROFECOXIB; TETRACYCLINE DERIVATIVE; TUMOR NECROSIS FACTOR ANTIBODY;

ALZHEIMER DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; ANIMAL MODEL; ANIMAL TISSUE; AUTOIMMUNE DISEASE; AUTOIMMUNITY; CANCER THERAPY; CELL THERAPY; CONTROLLED STUDY; GENE THERAPY; HUMAN; IMMUNE RESPONSE; IMMUNOMODULATION; IMMUNOSUPPRESSIVE TREATMENT; IMMUNOTHERAPY; MOUSE; MULTIPLE SCLEROSIS; NEUROLOGIC DISEASE; NEUROPROTECTION; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; RAT; SHORT SURVEY; TISSUE REPAIR; VACCINATION;

ALZHEIMER DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; ANIMALS; AUTOIMMUNE DISEASES; AUTOIMMUNITY; CYTOKINES; HUMANS; IMMUNOTHERAPY; INFLAMMATION; INFLAMMATION MEDIATORS; MESENCHYMAL STEM CELLS; MULTIPLE SCLEROSIS; NERVOUS SYSTEM DISEASES; NEURODEGENERATIVE DISEASES; PARKINSON DISEASE; STEM CELLS; T-LYMPHOCYTE SUBSETS;

EID: 49149125924     PISSN: 15216616     EISSN: 15217035     Source Type: Journal    
DOI: 10.1016/j.clim.2008.04.003     Document Type: Short Survey

References (60)

1. Melero I., Hervas-Stubbs S., Glennie M., Pardoll D.M., and Chen L. Immunostimulatory monoclonal antibodies for cancer therapy. Nat. Rev., Cancer 7 2 (2007) 95-106
2. Kim R., Emi M., Tanabe K., and Arihiro K. Tumor-driven evolution of immunosuppressive networks during malignant progression. Cancer Res. 66 11 (2006) 5527-5536
3. Suntharalingam G., Perry M.R., Ward S., Brett S.J., Castello-Cortes A., Brunner M.D., and Panoskaltsis N. Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412. N. Engl. J. Med. 355 10 (2006) 1018-1028
4. Sun Y., Lin X., Chen H.M., Wu Q., Subudhi S.K., Chen L., and Fu Y.X. Administration of agonistic anti-4-1BB monoclonal antibody leads to the amelioration of experimental autoimmune encephalomyelitis. J. Immunol. 168 3 (2002) 1457-1465
5. Smolen J.S., and Steiner G. Therapeutic strategies for rheumatoid arthritis. Nat. Rev. Drug Discov. 2 6 (2003) 473-488
6. Gutierrez-Canas I., Juarranz Y., Santiago B., et al. VIP down-regulates TLR4 expression and TLR4-mediated chemokine production in human rheumatoid synovial fibroblasts. Rheumatology (Oxford) 45 5 (2006) 527-532
7. Stuve O., Marra C.M., Cravens P.D., et al. Potential risk of progressive multifocal leukoencephalopathy with natalizumab therapy: possible interventions. Arch. Neurol. 64 2 (2007) 169-176
8. Kaiser J. Gene therapy. Questions remain on cause of death in arthritis trial. Science 317 5845 (2007) 1665
9. Schwartz M., and Kipnis J. Protective autoimmunity and neuroprotection in inflammatory and noninflammatory neurodegenerative diseases. J. Neurol. Sci. 233 1-2 (2005) 163-166
10. Butovsky O., Koronyo-Hamaoui M., Kunis G., Ophir E., Landa G., Cohen H., and Schwartz M. Glatiramer acetate fights against Alzheimer's disease by inducing dendritic-like microglia expressing insulin-like growth factor 1. Proc. Natl. Acad. Sci. U. S. A. 103 31 (2006) 11784-11789
11. Butovsky O., Bukshpan S., Kunis G., Jung S., and Schwartz M. Microglia can be induced by IFN-gamma or IL-4 to express neural or dendritic-like markers. Mol. Cell. Neurosci. 35 3 (2007) 490-500
12. Ziv Y., Avidan H., Pluchino S., Martino G., and Schwartz M. Synergy between immune cells and adult neural stem/progenitor cells promotes functional recovery from spinal cord injury. Proc. Natl. Acad. Sci. U. S. A. 103 35 (2006) 13174-13179
13. Montalban X. MS treatment: postmarketing studies. J. Neurol. Sci. 23 (2007) 23
14. Waubant E., Vukusic S., Gignoux L., Dubief F.D., Achiti I., Blanc S., Renoux C., and Confavreux C. Clinical characteristics of responders to interferon therapy for relapsing MS. Neurology 61 (2003) 184-189
15. Villoslada P., Oksenberg J.R., Rio J., and Montalban X. Clinical characteristics of responders to interferon therapy for relapsing MS. Neurology 62 9 (2004) 1653
16. Youssef S., Stuve O., Patarroyo J.C., et al. The HMG-CoA reductase inhibitor, atorvastatin, promotes a Th2 bias and reverses paralysis in central nervous system autoimmune disease. Nature 420 6911 (2002) 78-84
17. Vollmer T., Key L., Durkalski V., et al. Oral simvastatin treatment in relapsing-remitting multiple sclerosis. Lancet 363 9421 (2004) 1607-1608
18. Platten M., Ho P.P., Youssef S., et al. Treatment of autoimmune neuroinflammation with a synthetic tryptophan metabolite. Science 310 5749 (2005) 850-855
19. Moreno B., Hevia H., Santamaria M., et al. Methylthioadenosine reverses brain autoimmune disease. Ann. Neurol. 60 3 (2006) 323-334
20. Lawson B.R., Manenkova Y., Ahamed J., Chen X., Zou J.P., Baccala R., Theofilopoulos A.N., and Yuan C. Inhibition of transmethylation down-regulates CD4 T cell activation and curtails development of autoimmunity in a model system. J. Immunol. 178 8 (2007) 5366-5374
21. Gonzalez-Rey E., Chorny A., and Delgado M. Regulation of immune tolerance by anti-inflammatory neuropeptides. Nat. Rev., Immunol. 7 1 (2007) 52-63
22. Gonzalez-Rey E., and Delgado M. Vasoactive intestinal peptide and regulatory T-cell induction: a new mechanism and therapeutic potential for immune homeostasis. Trends Mol. Med. 26 (2007) 26
23. Zou W. Regulatory T cells, tumour immunity and immunotherapy. Nat. Rev., Immunol. 6 4 (2006) 295-307
24. Baecher-Allan C., and Hafler D.A. Human regulatory T cells and their role in autoimmune disease. Immunol. Rev. 212 (2006) 203-216
25. Martinez-Forero I., Garcia-Munoz R., Martinez A., et al. IL-10 suppressor activity and ex vivo Tr1 cell function are impaired in Multiple Sclerosis. Eur. J. Immunol. 38 2 (2008) 576-586
26. Hauben E., Agranov E., Gothilf A., Nevo U., Cohen A., Smirnov I., Steinman L., and Schwartz M. Posttraumatic therapeutic vaccination with modified myelin self-antigen prevents complete paralysis while avoiding autoimmune disease. J. Clin. Invest. 108 4 (2001) 591-599
27. Bar-Or A., Vollmer T., Antel J., et al. Induction of antigen-specific tolerance in multiple sclerosis after immunization with DNA encoding myelin basic protein in a randomized, placebo-controlled phase 1/2 trial. Arch. Neurol. 64 10 (2007) 1407-1415
28. Bielekova B., Goodwin B., Richert N., et al. Encephalitogenic potential of the myelin basic protein peptide (amino acids 83-99) in multiple sclerosis: results of a phase II clinical trial with an altered peptide ligand. Nat. Med. 6 10 (2000) 1167-1175
29. Ivanova N.B., Dimos J.T., Schaniel C., Hackney J.A., Moore K.A., and Lemischka I.R. A stem cell molecular signature. Science 298 5593 (2002) 601-604
30. Pluchino S., Quattrini A., Brambilla E., et al. Injection of adult neurospheres induces recovery in a chronic model of multiple sclerosis. Nature 422 6933 (2003) 688-694
31. Pluchino S., Zanotti L., Rossi B., et al. Neurosphere-derived multipotent precursors promote neuroprotection by an immunomodulatory mechanism. Nature 436 7048 (2005) 266-271
32. Uccelli A., Moretta L., and Pistoia V. Immunoregulatory function of mesenchymal stem cells. Eur. J. Immunol. 36 10 (2006) 2566-2573
33. Zappia E., Casazza S., Pedemonte E., et al. Mesenchymal stem cells ameliorate experimental autoimmune encephalomyelitis inducing T-cell energy. Blood 106 5 (2005) 1755-1761
34. Gerdoni E., Gallo B., Casazza S., et al. Mesenchymal stem cells effectively modulate pathogenic immune response in experimental autoimmune encephalomyelitis. Ann. Neurol. 61 3 (2007) 219-227
35. Uccelli A., Pistoia V., and Moretta L. Mesenchymal stem cells: a new strategy for immunosuppression?. Trends Immunol. 28 5 (2007) 219-226
36. Raivich G. Like cops on the beat: the active role of resting microglia. Trends Neurosci. 28 11 (2005) 571-573
37. Glezer I., Simard A.R., and Rivest S. Neuroprotective role of the innate immune system by microglia. Neuroscience 23 (2007) 23
38. Klegeris A., and McGeer P.L. Non-steroidal anti-inflammatory drugs (NSAIDs) and other anti-inflammatory agents in the treatment of neurodegenerative disease. Curr. Alzheimer Res. 2 3 (2005) 355-365
39. Acarin L., Gonzalez B., and Castellano B. Decrease of proinflammatory molecules correlates with neuroprotective effect of the fluorinated salicylate triflusal after postnatal excitotoxic damage. Stroke 33 10 (2002) 2499-2505
40. Lalancette-Hebert M., Gowing G., Simard A., Weng Y.C., and Kriz J. Selective ablation of proliferating microglial cells exacerbates ischemic injury in the brain. J. Neurosci. 27 10 (2007) 2596-2605
41. Lehnardt S., Lehmann S., Kaul D., et al. Toll-like receptor 2 mediates CNS injury in focal cerebral ischemia. J. Neuroimmunol. 190 1-2 (2007) 28-33
42. Lleo A., Galea E., and Sastre M. Molecular targets of non-steroidal anti-inflammatory drugs in neurodegenerative diseases. Cell. Mol. Life Sci. 20 (2007) 20
43. Simard A.R., Soulet D., Gowing G., Julien J.P., and Rivest S. Bone marrow-derived microglia play a critical role in restricting senile plaque formation in Alzheimer's disease. Neuron 49 4 (2006) 489-502
44. McGeer E.G., and McGeer P.L. Abeta immunotherapy and other means to remove amyloid. Curr. Drug Targets CNS Neurol. Disord. 4 5 (2005) 569-573
45. Gelinas D.S., DaSilva K., Fenili D., George-Hyslop P., and McLaurin J. Immunotherapy for Alzheimer's disease. Proc. Natl. Acad. Sci. U. S. A. 101 Suppl 2 (2004) 14657-14662
46. Zhang J., Wu X., Qin C., et al. A novel recombinant adeno-associated virus vaccine reduces behavioral impairment and beta-amyloid plaques in a mouse model of Alzheimer's disease. Neurobiol. Dis. 14 3 (2003) 365-379
47. Nicoll J.A., Barton E., Boche D., et al. Abeta species removal after abeta42 immunization. J. Neuropathol. Exp. Neurol. 65 11 (2006) 1040-1048
48. Engel T., Lucas J.J., Hernandez F., and Avila J. A mouse model to study tau pathology related with tau phosphorylation and assembly. J. Neurol. Sci. 13 (2007) 13
49. Oddo S., Billings L., Kesslak J.P., Cribbs D.H., and LaFerla F.M. Abeta immunotherapy leads to clearance of early, but not late, hyperphosphorylated tau aggregates via the proteasome. Neuron 43 3 (2004) 321-332
50. Olanow C.W., Obeso J.A., and Stocchi F. Continuous dopamine-receptor treatment of Parkinson's disease: scientific rationale and clinical implications. Lancet Neurol. 5 8 (2006) 677-687
51. FB, and Teismann P. Inhibition of the cyclooxygenase isoenzymes COX-1 and COX-2 provide neuroprotection in the MPTP-mouse model of Parkinson's disease. Synapse 39 2 (2001) 167-174
52. Wu D.C., Jackson-Lewis V., Vila M., et al. Blockade of microglial activation is neuroprotective in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson disease. J. Neurosci. 22 5 (2002) 1763-1771
53. Delgado M., and Ganea D. Neuroprotective effect of vasoactive intestinal peptide (VIP) in a mouse model of Parkinson's disease by blocking microglial activation. FASEB J. 17 8 (2003) 944-946
54. RE, Masliah E., Adame A., Alford M., Crews L., Hashimoto M., Seubert P., Lee M., Goldstein J., Chilcote T., Games D., and Schenk D. Effects of alpha-synuclein immunization in a mouse model of Parkinson's disease. Neuron 46 6 (2005) 857-868
55. Benner E.J., Mosley R.L., Destache C.J., et al. Therapeutic immunization protects dopaminergic neurons in a mouse model of Parkinson's disease. Proc. Natl. Acad. Sci. U. S. A. 101 25 (2004) 9435-9440
56. Clement A.M., Nguyen M.D., Roberts E.A., et al. Wild-type nonneuronal cells extend survival of SOD1 mutant motor neurons in ALS mice. Science 302 5642 (2003) 113-117
57. Beers D.R., Henkel J.S., Xiao Q., et al. Wild-type microglia extend survival in PU.1 knockout mice with familial amyotrophic lateral sclerosis. Proc. Natl. Acad. Sci. U. S. A. 103 43 (2006) 16021-16026
58. Angelov D.N., Waibel S., Guntinas-Lichius O., et al. Therapeutic vaccine for acute and chronic motor neuron diseases: implications for amyotrophic lateral sclerosis. Proc. Natl. Acad. Sci. U. S. A. 100 8 (2003) 4790-4795
59. PC, Azari M.F., Le Grande M.R., Lopes E.C., Hirst J., Petratos S., and Cheema S.S. Effects of intraperitoneal injection of Rofecoxib in a mouse model of ALS. Eur. J. Neurol. 12 5 (2005) 357-364
60. Nguyen M.D., Julien J.P., and Rivest S. Induction of proinflammatory molecules in mice with amyotrophic lateral sclerosis: no requirement for proapoptotic interleukin-1beta in neurodegeneration. Ann. Neurol. 50 5 (2001) 630-639